ArticleProceedings of the National Academy of Sciences of the United States of America1992
In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 223 citations in OpenAlex.
- Introduction and History of the Chemistry of Nucleic Acids Therapeutics.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Modeling the Hematopoietic Landscape.Frontiers in cell and developmental biology · 2019Review
- Anti-leukemic and anti-angiogenic effects of d-Limonene on K562-implanted C57BL/6 mice and the chick chorioallantoic membrane model.Animal models and experimental medicine · 2018Article
- Reassessing the Potential of Myb-targeted Anti-cancer Therapy.Journal of Cancer · 2018Review
- Review
- Article
- Expression of Slug is regulated by c-Myb and is required for invasion and bone marrow homing of cancer cells of different origin.The Journal of biological chemistry · 2010Article
- Article
- Gene expression profiles in acute myeloid leukemia with common translocations using SAGE.Proceedings of the National Academy of Sciences of the United States of America · 2006Article
- Review
- Animal models of acute myelogenous leukaemia - development, application and future perspectives.Leukemia · 2005Review
- Review
- Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.Wiener klinische Wochenschrift · 2003Review
- Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia.Proceedings of the National Academy of Sciences of the United States of America · 2003Article
- Review
- BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia.Oncogene · 2002Review
- Beta globin gene inhibition by antisense RNA transcripts.Gene therapy · 2000Article
- Antisense cancer therapy: the state of the science.Current oncology reports · 2000Review
- Review
- Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A.Proceedings of the National Academy of Sciences of the United States of America · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
The c-myb protooncogene encodes proteins that are critical for hematopoietic cell proliferation and development. Disrupting c-myb function might, therefore, prove an effective therapeutic strategy for controlling leukemic cell growth. Antisense oligodeoxynucleotides have been utilized for this purpose in vitro, but their in vivo efficacy has not been reported. We therefore established human leukemia-scid mouse chimeras with K562 cells and treated diseased animals with phosphorothioate-modified antisense oligodeoxynucleotides. K562 cells express the c-myb protooncogene, which served as the target for the antisense DNA. They also express the tumor-specific bcr-abl oncogene that was utilized to track the human cells in the mouse host. Once circulating leukemic blast cells had been detected, the survival of untreated control mice was 6 +/- 3 days (mean +/- SD). The survival of animals treated for 7 or 14 days with either sense or scrambled-sequence c-myb oligodeoxynucleotides was not statistically different from the control animals. In distinct contrast, animals treated for similar lengths of time with antisense c-myb oligodeoxynucleotides survived at least 3.5 times longer than the various control animals. In addition, animals receiving antisense c-myb DNA had significantly less disease at the two sites most frequently manifesting leukemic cell infiltration, the central nervous system and the ovary. These results suggest that phosphorothioate-modified antisense DNA may be efficacious for the treatment of human leukemia in vivo, and by analogy, for the treatment of other human neoplasias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.